An Open Label, First-in-human Study of BAY 2927088 in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) Harboring an EGFR and/or HER2 Mutation
Latest Information Update: 30 Aug 2024
At a glance
- Drugs BAY 2927088 (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; First in man; Pharmacokinetics
- Acronyms SOHO-01
- Sponsors Bayer
- 29 Aug 2024 According to a Bayer media release, Late-breaking results from this trial will be presented in the presidential symposium at the World Conference on Lung Cancer (WCLC) in San Diego on Monday, September 9th, 2024.
- 15 Aug 2024 Planned End Date changed from 30 Nov 2027 to 31 Dec 2026.
- 15 Aug 2024 Planned primary completion date changed from 30 Nov 2027 to 31 Dec 2025.